Intelligence Report · ~15 min read
Imaging · Contrast Agent Therapeutic Area Assessment
7 signals · 2 insights · 31 regulatory precedents
Type
Therapeutic Area AssessmentGenerated
Jul 23, 2026
Confidence
Moderate Confidence · 66%
Evidence
40 items
Sources
3
Executive Summary
Synthesized assessment from linked signals, findings, and evidence relationships.
Therapeutic area assessment for Imaging · Contrast Agent integrates 7 signals, 2 executive insights, and 31 regulatory precedents from the Humanexa intelligence graph. 0 portfolio assets maintain indication overlap in this area. Regulatory and competitive dynamics require cross-functional monitoring across linked entities.
Key Developments
Material intelligence events ranked by strategic relevance.
- signalJul 8, 2026
FDA Grants Approval for PIXXOSCAN (Gadobutrol) by GE Healthcare
The FDA has granted approval for PIXXOSCAN, a gadobutrol-based contrast agent submitted by GE Healthcare.
View detail - signalJul 19, 2026
Feasibility Study on IRE System for Adenotonsillar Hypertrophy in Children
A multi-center feasibility study is underway to assess the safety and efficacy of the IRE System for treating adenotonsillar hypertrophy in children.
View detail - signalJul 12, 2026
FDA Accepts Supplement Application for Gadobutrol by Hengrui Pharma
The FDA has accepted a supplemental application for Gadobutrol submitted by Hengrui Pharma.
View detail - signalJul 4, 2026
Metformin Aging Study to Assess Insulin Sensitivity and Mitochondrial Function
A 12-week double-blind, placebo-controlled trial will evaluate metformin's effects on insulin sensitivity and mitochondrial function in aging individuals.
View detail - regulatoryJul 19, 2026
[ANZEN]PMDA Alert for Proper Use of Drugs: Serious hypocarnitinemia and hypoglycaemia in children treated with antibacterials with a pivoxil group (follow-up report) posted
PMDA regulatory document relevant to this signal.
View detail - regulatoryJul 19, 2026
Pulmonary Valve Catheter Delivery System Recall: Medtronic Removes Harmony Delivery Catheter System (DCS)
The distal tip in certain lots of the Medtronic Harmony Delivery Catheter System (DCS) may detach which can require endovascular retrieval or surgical intervention.
View detail - regulatoryJul 19, 2026
FDA AP — CHILDREN'S ZYRTEC HIVES (SUPPL)
Application NDA022155. Sponsor: KENVUE BRANDS. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: CETIRIZINE HYDROCHLORIDE.
View detail - regulatoryJul 19, 2026
FDA AP — CHILDREN'S ADVIL-FLAVORED (SUPPL)
Application NDA020589. Sponsor: HALEON US HOLDINGS. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: IBUPROFEN.
View detail - insightJul 4, 2026
Metformin's Potential Expansion into Aging Therapies: Strategic Implications
The Metformin Aging Study could redefine the therapeutic landscape for aging-related interventions, potentially expanding metformin's indications beyond diabetes. Positive trial outcomes may prompt strategic shifts in portfolio management for companies involved in aging and metabolic health. Regulatory context from FDA (FDA AP — METFORMIN HYDROCHLORIDE (SUPPL)) supports the near-term read. Assessment grounded in 23 ranked evidence items (11 high-relevance).
View detail - insightJun 18, 2026
New Entrants in Gadobutrol Market Heighten Competitive Dynamics
The FDA's approval of Gadobutrol by Zenara signifies a new entrant in the contrast agent market, which could disrupt current pricing and market dynamics. Pharma strategy teams should closely monitor the competitive landscape as Zenara's market entry may lead to shifts in market share among established players. Regulatory context from FDA (FDA AP — GADOBUTROL (ORIG)) supports the near-term read. Assessment grounded in 19 ranked evidence items (16 high-relevance).
View detail
Strategic Implications
Portfolio and competitive decisions informed by this intelligence profile.
Executive insights surface 2 risk-calibrated assessments for portfolio review. 31 Regunera precedents provide regulatory context for pathway and timing decisions. Monitor 0 companies with active signal exposure for competitive and portfolio shifts.
Supporting Evidence
Evidence-backed items with source attribution and confidence disclosure.
[ANZEN]PMDA Alert for Proper Use of Drugs: Serious hypocarnitinemia and hypoglycaemia in children treated with antibacterials with a pivoxil group (follow-up report) posted
83%PMDA regulatory document relevant to this signal.
Source: PMDA
View evidencePulmonary Valve Catheter Delivery System Recall: Medtronic Removes Harmony Delivery Catheter System (DCS)
72%The distal tip in certain lots of the Medtronic Harmony Delivery Catheter System (DCS) may detach which can require endovascular retrieval or surgical intervention.
Source: FDA
View evidenceFDA AP — CHILDREN'S ZYRTEC HIVES (SUPPL)
72%Application NDA022155. Sponsor: KENVUE BRANDS. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: CETIRIZINE HYDROCHLORIDE.
Source: FDA
View evidenceFDA AP — CHILDREN'S ADVIL-FLAVORED (SUPPL)
72%Application NDA020589. Sponsor: HALEON US HOLDINGS. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: IBUPROFEN.
Source: FDA
View evidenceQuantitative Systems Pharmacology (QSP)-Based Dose Selection for Minimum Anticipated Biological Effect Level (MABEL) in First-in-Human (FIH) Trials
72%Why this matters: sets a safety guidance precedent in the same sub-indication (ild) as adenotonsillar hypertrophy treatment protocols.
Source: FDA
View evidenceGuidance Recap Podcast | Assessing the Effects of Food on Drugs in INDs and NDAs – Clinical Pharmacology Considerations
66%Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Hengrui Pharma; the same agency is already in play for this signal, so precedent weight is higher.
Source: FDA
View evidenceMetformin's Potential Expansion into Aging Therapies: Strategic Implications
67%The Metformin Aging Study could redefine the therapeutic landscape for aging-related interventions, potentially expanding metformin's indications beyond diabetes. Positive trial outcomes may prompt strategic shifts in portfolio management for companies involved in aging and metabolic health. Regulatory context from FDA (FDA AP — METFORMIN HYDROCHLORIDE (SUPPL)) supports the near-term read. Assessment grounded in 23 ranked evidence items (11 high-relevance).
Source: Humanexa Insight
View evidenceNew Entrants in Gadobutrol Market Heighten Competitive Dynamics
64%The FDA's approval of Gadobutrol by Zenara signifies a new entrant in the contrast agent market, which could disrupt current pricing and market dynamics. Pharma strategy teams should closely monitor the competitive landscape as Zenara's market entry may lead to shifts in market share among established players. Regulatory context from FDA (FDA AP — GADOBUTROL (ORIG)) supports the near-term read. Assessment grounded in 19 ranked evidence items (16 high-relevance).
Source: Humanexa Insight
View evidence
Related Intelligence
Deep links to signals, insights, companies, and assets in the Humanexa graph.
Signals
- FDA Grants Approval for PIXXOSCAN (Gadobutrol) by GE Healthcare
Regulatory Approval
- Feasibility Study on IRE System for Adenotonsillar Hypertrophy in Children
Trial Update
- FDA Accepts Supplement Application for Gadobutrol by Hengrui Pharma
Regulatory Approval
- Metformin Aging Study to Assess Insulin Sensitivity and Mitochondrial Function
Trial Update
- FDA Acceptance of Iohexol Supplement Application by Amneal
Regulatory Approval
- FDA Grants Approval for Gadobutrol ANDA219146 by Zenara
Regulatory Approval
- FDA Grants Approval for Gadobutrol ANDA219287 by Viwit Pharm
Regulatory Approval
Insights
- Metformin's Potential Expansion into Aging Therapies: Strategic Implications
Aging · Metformin
- New Entrants in Gadobutrol Market Heighten Competitive Dynamics
Imaging · Contrast Agent